Press release
Investgiation announced for Investors in Gamida Cell Ltd. (NASDAQ: GMDA shares
An investigation for investors in Gamida Cell Ltd. (NASDAQ: GMDA) shares over potential securities laws violations by Gamida Cell
Investors who purchased shares of Gamida Cell Ltd. (NASDAQ: GMDA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Gamida Cell Ltd. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Isreal based Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases.
On November 11, 2021, Gamida Cell Ltd provided an update on the Company's Pre-Biologics License Application ("BLA") meeting with the U.S. Food and Drug Administration for omidubicel, the Company's proposed blood cancer treatment. Specifically, Gamida Cell Ltd disclosed that "[t]he FDA requested that Gamida Cell provide revised analysis of the manufacturing data generated at Gamida Cell's wholly-owned commercial manufacturing facility to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites for the Phase 3 study," a development that the Company acknowledged would bring a "delay in timing to bring omidubicel to patients after a potential FDA approval[.]"
Shares of Gamida Cell Ltd. (NASDAQ: GMDA) declined from $4.56 per share on November 1, 2021, to as low as $2.25 per share on December 6, 2021.
Those who purchased shares of Gamida Cell Ltd. (NASDAQ: GMDA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investgiation announced for Investors in Gamida Cell Ltd. (NASDAQ: GMDA shares here
News-ID: 2492532 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Gamida
Hemoglobinopathies Market Growth Analysis: Industry Expansion and Key Players-Ga …
The Hemoglobinopathies Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.
Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/hemoglobinopathies-market
What is the projected growth…
Synthetic Stem Cells Market Next Big Thing| Major Giants Gamida Cell, Pluristem …
Advance Market Analytics published a new research publication on "Synthetic Stem Cells Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Synthetic Stem Cells market was mainly driven by the increasing R&D spending across the world.
Get Free Exclusive PDF Sample…
Investigation for NASDAQ: GMDA Investors announced over possible Wrongdoing at G …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Gamida Cell Ltd. .
Investors who purchased shares of Gamida Cell Ltd. (NASDAQ: GMDA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Gamida Cell Ltd. directors breached their fiduciary duties and caused damage to the company and its…
Natural Killer (NK) Cell Therapeutics Market 2021: Glycostem, Phio Pharmaceutica …
A new market study on the Natural Killer (NK) Cell Therapeutics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. Natural Killer (NK) Cell Therapeutics Market helps to see what factors are influencing the business, where the brand is situated, and get the complete assessment of the market before a product is launched. the report elucidates complex details about…
Tear Market Competitive Dynamics | Medtronic, Bolton Medical, Maquet, Gamida Cel …
Global Tear Market 2016-2020 is latest research study released by HTF MI evaluating the market status, highlighting opportunities, risk analysis, and leveraged with strategic decision-making support. The market Study is putting a lot of emphasis on regulatory issues, macro-economic influencing factors, key market trends and growth drivers that are changing the market dynamics of Global Tear market.
HTF’s analysts forecast the global TEAR market to grow at a CAGR of…
Gamida Cell Announces orphan drug designation for NiCord®
European Medicine Agency (EMA) has announced orphan drug status for NiCord® developed by Gamida cell, a leader in cellular and immune therapies for the treatment of cancer and orphan genetic diseases, to treat haematopoietic stem cell transplantation, also commonly known as bone marrow transplantation (BMT). Presently, the orphan drug is being evaluated internationally as a graft for bone marrow transplantation for patients with blood cancer who do not have a…
